[1]谭 奎,沈婵娟,张 玲,等.多发性骨髓瘤患者骨髓CD269和CD317基因的差异性表达研究[J].现代检验医学杂志,2017,32(06):64-66.[doi:10.3969/j.issn.1671-7414.2017.06.001]
　TAN Kui,SHEN Chan-juan,ZHANG Ling,et al.Differential Expression of CD269 and CD317 Genes in Bone Marrow of Patients with Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2017,32(06):64-66.[doi:10.3969/j.issn.1671-7414.2017.06.001]
点击复制

多发性骨髓瘤患者骨髓CD269和CD317基因的差异性表达研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第32卷
期数:
2017年06期
页码:
64-66
栏目:
论著
出版日期:
2017-12-25

文章信息/Info

Title:
Differential Expression of CD269 and CD317 Genes in Bone Marrow of Patients with Multiple Myeloma
文章编号:
1671-7414(2017)06-064-03
作者:
谭 奎; 沈婵娟; 张 玲; 刘玉霞; 李清照; 袁朝晖; 胡国瑜
株洲市中心医院血液科实验室,湖南株洲 412007
Author(s):
TAN Kui; SHEN Chan-juan; ZHANG Ling; LIU Yu-xia; LI Qing-zhao; YUAN Zhao-hui; HU Guo-yu
Department of Hematology Laboratory,Zhuzhou Central Hospital,Hunan Zhuzhou 412007,China
关键词:
多发性骨髓瘤;  CD269;  CD317;  实时定量PCR;  临床特征
分类号:
R733.3; R730.43
DOI:
10.3969/j.issn.1671-7414.2017.06.001
文献标志码:
A
摘要:
目的 探讨CD269和CD317在多发性骨髓瘤(MM)患者中的差异性表达。方法 收集株洲市中心医院血液内科2013年8月～2015年6月就诊的初诊多发性骨髓瘤(20例)患者和初诊缺铁性贫血(20例)患者骨髓标本共40例,应用实时定量PCR(RQ-PCR)检测骨髓标本中CD269和CD317,并结合临床特征对结果进行统计学分析。结果 多发性骨髓瘤患者CD269及CD317相对表达水平(4.418±4.568,4.327±2.876)高于对照组(0.600±0.838,1.033±1.335),差异有统计学意义(t=3.676,4.646,均P<0.05),且与患者的性别、年龄无关(P>0.05),两者之间表达无相关性(r=0.041,P=0.864),而与骨髓瘤细胞的比例呈正相关(r=0.495,P=0.026; r=0.533,P=0.016)。结论 CD269及CD317在多发性骨髓瘤患者高表达,可能参与多发性骨髓瘤的发病机制。
Abstract:
Abstract:Objective To explore the differential expression of CD269 and CD317 in patients with multiple myeloma(MM).MethodsNewly diagnosed samles from patients of MM(20 cases)and iron deficiency anemia(20 cases),40 cases in total(from 06/2015 to 08/2013,the Department of Hematology,Central Hospital of Zhuzhou City)were collected.Real-time quantitative PCR(RQ - PCR)tests were used to detect the relative expression ofCD269 and CD317 in bone marrow samples,and the results were statistically analyzed with clinical features.Results The relative expression levels of CD269 and CD317 in patients with multiple myeloma(4.418±4.568,4.327±2.876)were significantly higher than those in the control group(0.600±0.838,1.033±1.335),the difference was statistically significant(t=3.676,4.646,all P<0.05)respectively,while not related with the gender,age(P>0.05).There was no correlation between the expression of CD269and CD317(r=0.041,P=0.864),but positively correlated with the ratio ofmyeloma cells(r=0.495,P=0.026; r=0.533,P=0.016).Conclusion CD269 and CD317 were highly expressed in patients with multiple myeloma and may be involved in the pathogenesis of multiple myeloma.

参考文献/References:

[1] O'Connor BP,Raman VS,Erickson LD,et al.BCMA is essential forthe survival of long-lived bone marrow plasma cells[J].J Exp Med,2004,199(1):91-98.
[2] Fang KH,Kao HK,Chi LM,et al.Overexpression of BST2 is associated withnodal metastasis and poorer prognosis in oral cavity cancer[J].Laryngoscope,2014,124(9):354-360.
[3] Gong S,Osei ES,Kaplan D,et al.CD317 is over-expressed in B-cell chronic lymphocytic leukemia,but not B-cell acute lymphoblastic leukemia[J].International Journal of Clinical & Experimental Pathology,2015,8(2):1613-1621.
[4] Mahauad-Ferandez WD,Borcherding NC,Zhang W,et al.Bone marrow stromalantigen 2(BST-2)DNA is demethylated in breast tumors and breast cancer cells[J].PLoS One,2015,10(4):e0123931.
[5] Siegel R,Ma J,Zou ZH,et al.Cancer statistics,2014[J].CA Cancer JClin,2014,64(5):9-29.
[6] Shu HB,Johnson H.B cell maturation protein is a receptor for the tumornecrosis facror family memberTALL-1[J].Proc Natl Acad Sci USA,2000,97(16):9156-9161.
[7] 徐 光,班永宏,鞠少卿,等.JNK信号通路活化与BCMA表达对MM细胞的作用研究[J].国际检验医学杂志,2016,37(22):3117-3119,3122. Xu G,Ban YH,Ju SQ,et al.Interaction betwen JNK signal pathway activation and BCMA expression collectively promotes the survival of multiple myeloma cells[J].Int J Lab Med,2016,37(22):3117-3119,3122.
[8] Ishikawa J,Kaisho T,Tomizawa H,et al.Molecular cloning and chromosomal mapping of a bone marrow stromal cell surface gene,BST2,that may be involvedin pre-B-cell growth[J].Genomics,1995,26(3):527-534.
[9] Goto T,Kenel SJ,Abe M,et al.A novel membrane antigen selectively expressed on terminally differentiated human B-cell[J].Blood,1994,84(6):1922-1930.
[10] 王金湖,倪红兵,王旭东,等.多发性骨髓瘤患者B淋巴细胞刺激因子及其受体的表达水平[J].现代检验医学杂志,2009,24(2):39-41. Wang JH,Ni HB,Wang XD,et al.Correlation of expression levels of B lysand its receptors in patients with multiple myeloma[J].J Mod Lab Med,2009,24(2):39-41.
[11] Carpenter RO,Evbuomwan MO,Pittaluga S,et al.B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma[J].Clin Cancer Res,2013,19(8),2048-2060.
[12] Chiriva-Internati M,Liu Y,Weidanz JA,et al.Testing recombinant adeno-associated virus-gene loading of dendritic cells for generating potent cytotoxic T lymphocytes against a prototype self-antigen,multiple myeloma HM1.24[J].Blood,2003,102(9):3100-3107. 收稿日期:2017-07-05 修回日期:2017-08-21

相似文献/References:

[1]韩秀蕊,杨娣娣,李艳春,等.多发性骨髓瘤患者骨髓涂片与骨髓活检同步检查的比较分析[J].现代检验医学杂志,2015,30(03):129.[doi:10.3969/j.issn.1671-7414.2015.03.039]
　HAN Xiu-rui,YANG Di-di,LI Yan-chun,et al.Comparative Analysis of Bone Marrow Smears and Biopsies Synchronous Check for Myeloma Patients[J].Journal of Modern Laboratory Medicine,2015,30(06):129.[doi:10.3969/j.issn.1671-7414.2015.03.039]
[2]邱 爽,孟瑞芳,蒋筱漪,等.血清免疫固定电泳、蛋白电泳、免疫球蛋白及轻链定量在诊断多发性骨髓瘤中的临床应用[J].现代检验医学杂志,2015,30(02):61.[doi:10.3969/j.issn.1671-7414.2015.02.019]
　QIU Shuang,MENG Rui-fang,JIANG Xiao-yi,et al.Clinical Application of Immunofixtion Electrophoresis, Serum Protein Electrophoresis and Immunoglobulins and Light Chain Quantitative Analysis in the Diagnosis of Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2015,30(06):61.[doi:10.3969/j.issn.1671-7414.2015.02.019]
[3]李 瑛,李 军.多发性骨髓瘤患者血清中IL-6与IL-27水平监测的临床应用[J].现代检验医学杂志,2016,31(04):87.[doi:10.3969/j.issn.16717-414.2016.04.023]
　LI Ying,LI Jun.Clinical Application of Monitoring IL-6 and IL-27 Levels in Patients with Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2016,31(06):87.[doi:10.3969/j.issn.16717-414.2016.04.023]
[4]郭进京,胡林辉,陶千山,等.红细胞分布宽度在多发性骨髓瘤患者预后分期中的价值[J].现代检验医学杂志,2017,32(03):34.[doi:10.3969/j.issn.1671-7414.2017.03.009]
　GUO Jin-jing,HU Lin-hui,TAO Qian-shan,et al.Value of Red Cell Distribution Width in the Prognosis of Patients with Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2017,32(06):34.[doi:10.3969/j.issn.1671-7414.2017.03.009]
[5]盘国雄,谭才燕,何嘉颖,等.多发性骨髓瘤患者血清中lncRNA PCAT-1的表达水平与临床预后研究[J].现代检验医学杂志,2018,33(01):72.[doi:10.3969/j.issn.1671-7414.2018.01.001]
　PAN Guo-xiong,TAN Cai-yan,HE Jia-ying,et al.Serum LncRNA PCAT-1 Expression Level of Patients with Multiple Myeloma and Clinical Value[J].Journal of Modern Laboratory Medicine,2018,33(06):72.[doi:10.3969/j.issn.1671-7414.2018.01.001]
[6]张 蓉,李国辉,刘小五,等.初诊多发性骨髓瘤患者外周血淋巴细胞绝对值/ 单核细胞绝对值比值在预测临床预后的价值研究[J].现代检验医学杂志,2020,35(01):101.[doi:10.3969/j.issn.1671-7414.2020.01.027]
　ZHANG Rong,LI Guo-hui,LIU Xiao-wu,et al.Value of Peripheral Blood Lymphocyte Absolute Value/Monocyte Absolute Value Ratio in Predicting Clinical Prognosis of Newly Diagnosed MultipleMyeloma Patients[J].Journal of Modern Laboratory Medicine,2020,35(06):101.[doi:10.3969/j.issn.1671-7414.2020.01.027]
[7]霍 豆,秦 爽,吴永昌,等.血清总轻链与游离轻链定量检测在多发性骨髓瘤诊断中的临床价值探讨[J].现代检验医学杂志,2020,35(04):87.[doi:10.3969/j.issn.1671-7414.2020.04.021]
　HUO Dou,QIN Shuang,WU Yong-chang,et al.Clinical Value of Quantitative Detection of sTLC and sFLC in Diagnosis of Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2020,35(06):87.[doi:10.3969/j.issn.1671-7414.2020.04.021]
[8]何　进,张　艳,申娴娟,等.多发性骨髓瘤患者血清可溶性PD-L1水平在辅助诊断及临床分型的价值研究[J].现代检验医学杂志,2021,36(02):15.[doi:doi:10.3969/j.issn.1671-7414.2021.02.004]
　HE Jin,ZHANG Yan,SHEN Xian-juan,et al.Value of Blood Soluble PD-L1 in the Auxiliary Diagnosis and Clinical Subtype of Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2021,36(06):15.[doi:doi:10.3969/j.issn.1671-7414.2021.02.004]
[9]徐海燕,陆学东.多发性骨髓瘤早期实验诊断相关新兴生物标志物的最新研究进展[J].现代检验医学杂志,2021,36(05):180.[doi:10.3969/j.issn.1671-7414.2021.05.039]
　XU Hai-yan,LU Xue-dong.Recent Research Rrogress of Novel Biomarkers for Early ExperimentalDiagnosis of Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2021,36(06):180.[doi:10.3969/j.issn.1671-7414.2021.05.039]
[10]侯艳军,张秋怡,单志娟,等.多发性骨髓瘤患者骨髓中CD56和CD117水平表达对评估疾病预后的价值[J].现代检验医学杂志,2021,36(06):74.[doi:10.3969/j.issn.1671-7414.2021.06.015]
　HOU Yan-jun,ZHANG Qiu-yi,SHAN Zhi-juan,et al.Significance of the Expression of CD56 and CD117 in Evaluating the Prognosis of Patients with Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2021,36(06):74.[doi:10.3969/j.issn.1671-7414.2021.06.015]
[11]刘玉霞,胡国瑜,袁朝晖,等.CD269和CD317在多发性骨髓瘤中的表达及临床意义[J].现代检验医学杂志,2018,33(02):58.[doi:10.3969/j.issn.1671-7414.2018.02.001]
　LIU Yu-xia,HU Guo-yu,YUAN Chao-hui,et al.Expression of CD269 and CD317 in Multiple Myeloma and Its Clinical Significance[J].Journal of Modern Laboratory Medicine,2018,33(06):58.[doi:10.3969/j.issn.1671-7414.2018.02.001]

备注/Memo

备注/Memo:
基金项目:湖南省卫计委科研项目,课题编号C2015-075。 作者简介:谭 奎(1984-),女,硕士,助理研究员,主要研究方向:血液系统疾病,E-mail:181925861@qq.com。 通讯作者:胡国瑜,E-mail:doctorhgy@163.com。
更新日期/Last Update: 2017-12-26